Certara Services Archives

Publication

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…

CertaraFebruary 6, 2025

Press Coverage

2025 cell and gene challenges: Scalability, supply chain and manufacturing

Explore insights on 2025 challenges in cell and gene therapy, including commercial viability, with expert…

CertaraFebruary 3, 2025

Blog

Best Practices for International Pharma Content Roll-Out

January 31, 2025 Pharmaceutical market access, sales, and field teams rely on high-quality, effective content…

CertaraJanuary 31, 2025

Press Coverage

How do you see advances in personalized medicine reshaping patient care, and what are the key challenges and opportunities ahead?

Discover how advances in personalized medicine are reshaping patient care, and why biosimulation will become…

CertaraJanuary 31, 2025

On-Demand Webinar

Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions

Vice President and Head of Global PK/PD and Pharmacometrics at Eli Lilly and Company Dr.…

CertaraJanuary 29, 2025

Press Coverage

What 2025 could bring for psychedelic use in healthcare

Explore the evolving landscape of psychedelic medicine, featuring updates from key players and insights on…

CertaraJanuary 13, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

CertaraJanuary 9, 2025

Publication

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

CertaraJanuary 8, 2025

On-Demand Webinar

Where to Start? Setting Your Medical Writing Team Up for Success with GenAI

Generative AI (GenAI) is poised to revolutionize writing and report generation. In fact, industry studies…

CertaraJanuary 6, 2025

Press Coverage

Pharma – 2025 Health IT Predictions

Discover transformative 2025 Health IT predictions, from AI in drug discovery to personalized medicine and…

CertaraJanuary 3, 2025

Certara Services

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

2025 cell and gene challenges: Scalability, supply chain and manufacturing

Best Practices for International Pharma Content Roll-Out

How do you see advances in personalized medicine reshaping patient care, and what are the key challenges and opportunities ahead?

Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions

What 2025 could bring for psychedelic use in healthcare

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Where to Start? Setting Your Medical Writing Team Up for Success with GenAI

Pharma – 2025 Health IT Predictions

Newsletter sign up

Quick links

Solutions

Contact